NeuBase Financial Statements From 2010 to 2024

NBSE Stock  USD 0.43  0.05  10.42%   
NeuBase Therapeutics financial statements provide useful quarterly and yearly information to potential NeuBase Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NeuBase Therapeutics financial statements helps investors assess NeuBase Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NeuBase Therapeutics' valuation are summarized below:
Market Capitalization
1.8 M
Earnings Share
(18.60)
There are over one hundred nineteen available fundamental ratios for NeuBase Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of NeuBase Therapeutics' last-minute performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road.
Check NeuBase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuBase main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 20.6 K or Selling General Administrative of 14.3 M, as well as many exotic indicators such as Short Term Coverage Ratios of 7.0, Price Earnings Ratio of 246 or Price To Sales Ratio of 1.85. NeuBase financial statements analysis is a perfect complement when working with NeuBase Therapeutics Valuation or Volatility modules.
  
This module can also supplement NeuBase Therapeutics' financial leverage analysis and stock options assessment as well as various NeuBase Therapeutics Technical models . Check out the analysis of NeuBase Therapeutics Correlation against competitors.
For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.

NeuBase Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets39.5 M37.6 M27.4 M
Slightly volatile
Short and Long Term Debt Total7.2 M6.9 M2.2 M
Slightly volatile
Total Current Liabilities2.5 M4.8 M3.1 M
Slightly volatile
Total Stockholder Equity13.9 M26.7 M21.3 M
Slightly volatile
Property Plant And Equipment Net9.4 M8.9 MM
Slightly volatile
Non Current Assets Total5.8 M9.3 MM
Very volatile
Cash And Short Term Investments28 M26.6 M18.3 M
Slightly volatile
Net Receivables154.2 K146.9 K122.7 K
Slightly volatile
Common Stock Total EquityK2.1 K63.3 K
Slightly volatile
Common Stock Shares Outstanding1.9 M1.9 M689.1 K
Slightly volatile
Short Term Investments293.1 K372.1 K321.9 K
Slightly volatile
Liabilities And Stockholders Equity39.5 M37.6 M27.4 M
Slightly volatile
Non Current Liabilities Total6.4 M6.1 M2.2 M
Slightly volatile
Total Liabilities11.5 M10.9 M5.2 M
Slightly volatile
Property Plant And Equipment Gross10.9 M10.4 M3.4 M
Slightly volatile
Total Current Assets29.8 M28.3 M19.1 M
Slightly volatile
Short Term Debt797.8 K759.8 K281.5 K
Slightly volatile
Common Stock2.8 KK63.6 K
Slightly volatile
Accounts Payable1.6 M1.7 M17.3 M
Slightly volatile
Cash19.8 M20.8 M30.5 M
Slightly volatile
Intangible Assets159.3 K167.7 K6.1 M
Slightly volatile
Capital Surpluse31.7 M33.3 M66.9 M
Slightly volatile
Property Plant Equipment9.4 M8.9 MM
Slightly volatile
Short and Long Term Debt124.2 K170.6 K113.9 K
Slightly volatile
Net Invested Capital28 M26.7 M24.6 M
Pretty Stable
Non Current Liabilities Other120 K135 K147 K
Slightly volatile
Net Working Capital22.1 M23.6 M15.7 M
Slightly volatile
Long Term Debt200 K225 K245 K
Slightly volatile
Capital Stock2.6 KK4.3 K
Slightly volatile
Current Deferred Revenue528.8 K639.3 K469.5 K
Slightly volatile

NeuBase Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM952.7 K658.8 K
Slightly volatile
Interest Expense20.6 K21.6 K144 K
Very volatile
Selling General Administrative14.3 M13.7 M7.8 M
Slightly volatile
Other Operating Expenses40.2 M38.3 M20.7 M
Slightly volatile
Research Development18.3 M19.3 M11.7 M
Slightly volatile
Cost Of Revenue1.1 M1.1 M11.2 M
Slightly volatile
Non Recurring3.5 MMM
Slightly volatile
Reconciled Depreciation582 K1.1 M956 K
Slightly volatile

NeuBase Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow63.9 M60.8 M23.2 M
Slightly volatile
Depreciation1.5 M1.5 M777.7 K
Slightly volatile
End Period Cash Flow28 M26.6 M18.4 M
Slightly volatile
Change To InventoryB1.1 B1.2 B
Slightly volatile
Dividends Paid557.1 K586.4 K2.4 M
Slightly volatile
Change To Netincome3.6 M3.8 M6.5 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.851.955.0361
Slightly volatile
Dividend Yield0.01350.01420.0239
Slightly volatile
Days Of Payables Outstanding5826132.6 K
Slightly volatile
Pretax Profit Margin0.01530.01610.4896
Slightly volatile
Ebt Per Ebit0.00630.00660.7456
Slightly volatile
Payables Turnover1.430.790.6671
Pretty Stable
Operating Profit Margin3.622.23.0975
Slightly volatile
Long Term Debt To Capitalization0.01640.01720.418
Slightly volatile
Cash Per Share1.111.171.2 K
Slightly volatile
Total Debt To Capitalization0.05270.05540.3708
Slightly volatile
Ebit Per Revenue3.622.23.0975
Slightly volatile
Quick Ratio1.21.2622.4865
Slightly volatile
Cash Ratio6.076.3926.1226
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.260.921.1294
Slightly volatile
Current Ratio0.940.994.7799
Very volatile
Fixed Asset Turnover32.8256.9946.0589
Slightly volatile
Debt Ratio0.03760.03960.0602
Pretty Stable
Price Sales Ratio1.851.955.0361
Slightly volatile
Asset Turnover2.964.743.848
Slightly volatile

NeuBase Fundamental Market Drivers

Cash And Short Term Investments23.2 M

NeuBase Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

About NeuBase Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include NeuBase Therapeutics income statement, its balance sheet, and the statement of cash flows. NeuBase Therapeutics investors use historical funamental indicators, such as NeuBase Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although NeuBase Therapeutics investors may use each financial statement separately, they are all related. The changes in NeuBase Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NeuBase Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on NeuBase Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in NeuBase Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue639.3 K528.8 K
Total Revenue 0.00  0.00 
Cost Of Revenue1.1 M1.1 M
Ebit Per Revenue 2.20  3.62 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NeuBase Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NeuBase Therapeutics' short interest history, or implied volatility extrapolated from NeuBase Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether NeuBase Therapeutics is a strong investment it is important to analyze NeuBase Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NeuBase Therapeutics' future performance. For an informed investment choice regarding NeuBase Stock, refer to the following important reports:
Check out the analysis of NeuBase Therapeutics Correlation against competitors.
For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for NeuBase Stock analysis

When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.60)
Return On Assets
(0.43)
Return On Equity
(0.93)
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.